Precigen, Inc. (NASDAQ:PGEN - Get Free Report) CFO Harry Jr. Thomasian sold 100,000 shares of the firm's stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $6.06, for a total value of $606,000.00. Following the transaction, the chief financial officer directly owned 254,535 shares in the company, valued at approximately $1,542,482.10. The trade was a 28.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harry Jr. Thomasian also recently made the following trade(s):
- On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The stock was sold at an average price of $5.53, for a total value of $948,002.37.
- On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The shares were sold at an average price of $5.78, for a total value of $165,140.38.
- On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.
Precigen Stock Up 5.6%
Shares of NASDAQ PGEN opened at $6.27 on Friday. The business has a 50-day moving average price of $4.98 and a 200 day moving average price of $4.41. The stock has a market cap of $2.24 billion, a PE ratio of -5.31 and a beta of 1.00. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. Precigen, Inc. has a 52-week low of $1.63 and a 52-week high of $6.28.
Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The company had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. Equities research analysts forecast that Precigen, Inc. will post -0.02 earnings per share for the current year.
Institutional Trading of Precigen
A number of hedge funds have recently added to or reduced their stakes in the stock. State of Wyoming purchased a new position in shares of Precigen in the 1st quarter valued at approximately $27,000. NBC Securities Inc. acquired a new position in shares of Precigen in the fourth quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Precigen during the third quarter worth approximately $39,000. Royal Bank of Canada raised its stake in shares of Precigen by 102.6% during the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 5,426 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Precigen during the third quarter worth $41,000. 33.51% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Citigroup reaffirmed an "outperform" rating on shares of Precigen in a report on Thursday, May 14th. Citizens Jmp increased their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Precigen from a "buy" rating to a "hold" rating in a research report on Sunday, May 31st. HC Wainwright raised their price objective on shares of Precigen from $11.00 to $14.00 and gave the stock a "buy" rating in a research report on Thursday, May 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Precigen in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $12.50.
Read Our Latest Stock Analysis on Precigen
Precigen Company Profile
(
Get Free Report)
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
